Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
For kidney transplant immunosuppression: Protection in a hostile environment
Thymoglobulin® is the only T-cell-depleting agent that is FDA approved for prophylaxis of acute rejection.1-3

Multiple Risk factors should be considered when evaluating the risk for acute rejection.4,5

Thymoglobulin may induce immunosuppression through multiple pathways.1

Learn more about clinical trial data supporting the use of Thymoglobulin.

The approved dose of Thymoglobulin offers clinically demonstrated protection for your patient's new kidney.1

Important Safety Information for Thymoglobulin
[Anti-thymocyte Globulin (Rabbit)]:

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Important Safety Information for Thymoglobulin [Anti-thymocyte Globulin (Rabbit)]:

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Click here for full Prescribing Information including Boxed WARNING.

References:
  1. Thymoglobulin [prescribing information]. Cambridge, MA: Genzyme Corporation; 2017.
  2. Atgam [prescribing information]. New York, NY: Pfizer, Inc.; 2015.
  3. Campath [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  4. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant. 2015;15 Suppl 2:1-34.
  5. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant. 2016;16 suppl 2:11-46.